年报密集披露期,业绩的改善并未给欧康维视生物-B(01477)带来显著的上行动力。截至4月16日收盘,公司股价连续2日下行,收于4.78港元,市值已然低于40亿港元的“保通”门槛。公开资料显示,欧康维视生物是一家中国眼科医药平台公司,致力于识别、开发和商业化同类首创或同类最佳的眼科疗法。其不仅身处眼科这一“黄金赛道”,且产品管线中已拥有三十余种药物资源,更有多款产品进入商业化,推动公司全年营收录得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.